Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, January 4th. The firm presently has a $1.25 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 1.63% from the stock’s previous close.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
Several other research firms have also recently commented on RGLS. Wedbush restated an “outperform” rating and set a $4.00 price target on shares of Regulus Therapeutics in a report on Monday, December 11th. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. Regulus Therapeutics has a consensus rating of “Hold” and an average target price of $2.46.
Shares of Regulus Therapeutics (NASDAQ RGLS) traded up $0.02 on Thursday, hitting $1.23. 586,224 shares of the company’s stock traded hands, compared to its average volume of 710,143. Regulus Therapeutics has a one year low of $0.79 and a one year high of $2.60. The firm has a market capitalization of $127.86, a PE ratio of -0.92 and a beta of 1.55. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. NEA Management Company LLC acquired a new position in Regulus Therapeutics during the 3rd quarter worth approximately $13,737,000. FMR LLC boosted its holdings in shares of Regulus Therapeutics by 0.5% in the 2nd quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after purchasing an additional 37,489 shares in the last quarter. EcoR1 Capital LLC boosted its holdings in shares of Regulus Therapeutics by 145.6% in the 2nd quarter. EcoR1 Capital LLC now owns 3,709,144 shares of the biopharmaceutical company’s stock worth $3,656,000 after purchasing an additional 2,199,144 shares in the last quarter. South Dakota Investment Council boosted its holdings in shares of Regulus Therapeutics by 37.1% in the 3rd quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock worth $2,275,000 after purchasing an additional 492,969 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. purchased a new position in shares of Regulus Therapeutics in the 3rd quarter worth about $750,000. 59.39% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This news story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://ledgergazette.com/2018/01/12/regulus-therapeutics-rgls-upgraded-to-buy-by-zacks-investment-research.html.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.